If you're looking to put cash into two fantastic biotech stocks that Wall Street seems particularly bullish on, there's one ...

Regeneron topped Wall Street estimates for second-quarter results on Friday, on robust demand for its blockbuster eczema drug ...

Q2 2025 Earnings Call Transcript August 1, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Regeneron develops, manufactures, and markets medicines for serious diseases with a primary focus on immunology, ophthalmology, oncology, and rare conditions. Its scientific model centers on a robust ...